Cognition Therapeutics, Inc. presented biomarker results from its Phase 2 SHINE study of zervimesine (CT1812) in mild-to-moderate Alzheimer’s disease at the AD/PD™ 2025 conference. The presentation highlighted changes in key proteins, or biomarkers, in both the overall study population and a specific subgroup.
In the overall study population, zervimesine treatment for six months led to reductions in plasma biomarkers associated with Alzheimer’s disease processes compared to placebo. A more pronounced reduction in glial fibrillary acidic protein (GFAP), linked to neuroinflammation, and neurofilament light (NfL), associated with neurodegeneration, was observed in the low-p-Tau217 subgroup.
Additionally, amyloid beta (Aβ) and p-Tau217 levels were lower in zervimesine-treated participants. These findings correlate with the cognitive effects previously observed and support zervimesine’s mechanism of action in impacting the underlying biology of Alzheimer’s disease.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.